Roivant Sciences is a healthcare company focused on developing innovative therapies through its unique business model that emphasizes the rapid advancement of drug candidates. Its core products include a range of biopharmaceuticals targeting various diseases, with major business segments encompassing drug development and commercialization. The company generates revenue primarily from partnerships, licensing agreements, and potential product sales.
The investment profile of Roivant Sciences is more aligned with growth investors, given its focus on innovative drug development and potential for future revenue generation. The stock may appeal to those looking for exposure to the healthcare sector with a longer-term perspective, as it is still in the developmental phase.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-09 | — | Hold | Strong momentum, but fundamentals show significant weakness. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-09 | Guggenheim | Target Raised | — → 46 | 41.48 |
| 2026-09-09 | UBS | Target Raised | — → 55 | 41.48 |
| 2026-09-08 | H.C. Wainwright | Target Raised | 41 → 47 | 42.0275 |
| 2026-09-08 | Jefferies | Target Raised | 42 → 52 | 41.701 |
| 2026-08-07 | H.C. Wainwright | Target Raised | 34 → 41 | 35.12 |
| 2026-05-26 | Guggenheim | Target Raised | 30 → 36 | 29.96 |
| 2026-05-21 | Cowen & Co. | Target Raised | 38 → 41 | 32.18 |
| 2026-05-21 | Leerink Partners | Target Raised | — → 42 | 32.41 |
| 2026-04-16 | Piper Sandler | Update | — → 40 | 29.26 |
| 2026-03-04 | H.C. Wainwright | Target Raised | — → 34 | 28.8147 |
| 2026-02-10 | H.C. Wainwright | Target Raised | 26 → 33 | 27.67 |
| 2026-02-09 | Jefferies | Target Raised | 24 → 30 | 26.445 |
